Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

CUSIP: 03168L105

Q3 2023 13F Holders as of 30 Sep 2023

Holder snapshot 7 signals
Share change
+4,473,275
Put/Call ratio
1.8%
SEC-reported price per share
$4.22
Number of holders
141
Value change
+$19,693,333
Number of buys
84
Open additional details 1 more signal available
Number of sells
44
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
348,532,261

Security key

03168L105

Report period

Q3 2023

Institutions

141

Top holders

10

Ownership snapshot

Top reported holders of AMRX - Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
TPG GP A, LLC
Disclosed value leader
Fosun International Ltd
Comparable rows
0/15
Latest evidence
30 Jun 2023
3/4/5 13F Highest disclosed value: $66,716,032 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Fosun International Ltd has the largest disclosed position value at $66.72M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Fosun International Ltd's linked filing trail.
Disclosed position value Top 5
TPG GP A, LLC $50.88M
Fosun International Ltd $66.72M
VANGUARD GROUP INC $40.72M
BlackRock Finance, Inc. $24.82M
Eversept Partners, LP $16.32M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
TPG GP A, LLC
3/4/5 13F
Former 10% Owner · Company
—
denominator unverified
$50,877,123
12,328,767 shares
— 12 Dec 2022
Fosun International Ltd
13F
Company
13F
—
denominator unverified
$66,716,032
21,521,301 shares
— 30 Jun 2023
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$40,720,673
13,135,701 shares
— 30 Jun 2023
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$24,824,787
8,007,996 shares
— 30 Jun 2023
Eversept Partners, LP
13F
Company
13F
—
denominator unverified
$16,322,278
5,265,251 shares
— 30 Jun 2023
Neuberger Berman Group LLC
13F
Company
13F
—
denominator unverified
$11,539,269
3,747,939 shares
— 30 Jun 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
141
Shares
101,896,343
Rows available
141
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders
122
Q3 2023 holders
141
Holder diff
19
Investor Q2 2023 Shares Q3 2023 Shares Share Diff Share Chg % Q2 2023 value Q3 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .